Literature DB >> 22561141

Comparison of dual- and triple-freeze protocols for hepatic cryoablation in a Tibet pig model.

Jialiang Li1, Jibing Chen, Liang Zhou, Jianying Zeng, Fei Yao, Binghui Wu, Gang Fang, Chunjuan Deng, Zhixian Chen, Yin Leng, Keqiang Xu, Lizhi Niu, Jiansheng Zuo, Kecheng Xu.   

Abstract

The purpose of this study was to compare a dual-freeze protocol with a triple-freeze protocol for hepatic cryoablation in a porcine model. Eighteen cryoablations were performed over an exposed operation field in nine normal porcine livers, using dual- (10-5-10-5) and triple-freeze (5-5-5-5-10-5) protocols. Changes in the temperature of the cryoprobes and the diameter of the iceballs were recorded during the ablation, and pathological changes in the cryozones (zones of tissue destruction) were assessed seven days after the procedure. Use of two and three freeze-thaw cycles produced iceballs of different diameters. Seven days after cryosurgery, the triple-freeze protocol was associated with a larger zone of complete necrosis than the dual-freeze protocol, although the two protocols produced cryozones and cryolesions of similar length, and in both cases the cryozones contained five areas of destruction. With the same freezing time (20 min), the triple-freeze protocol may be a more powerful liver ablation method than the dual-freeze protocol.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22561141     DOI: 10.1016/j.cryobiol.2012.04.004

Source DB:  PubMed          Journal:  Cryobiology        ISSN: 0011-2240            Impact factor:   2.487


  3 in total

Review 1.  Percutaneous Cryoablation for Liver Cancer.

Authors:  Li-Zhi Niu; Jia-Liang Li; Ke-Cheng Xu
Journal:  J Clin Transl Hepatol       Date:  2014-09-15

2.  Percutaneous cryoablation for hepatocellular carcinoma.

Authors:  Kyoung Doo Song
Journal:  Clin Mol Hepatol       Date:  2016-12

Review 3.  Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation.

Authors:  Kijung Kwak; Bo Yu; Robert J Lewandowski; Dong-Hyun Kim
Journal:  Theranostics       Date:  2022-02-14       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.